Autologous Transplant Targeted Against Crohn's
NCT04154735
Withdrawn
This study is a new Phase II trial to assess the toxicity and efficacy of autologous hematopoietic stem cell transplantation (HSCT) utilizing a new non-myeloablative conditioning regimen in patients with high-risk Crohn's disease (CD). The regimen will include low-dose immunosuppressive therapy and a targeted antibiotic for six to twelve months post-HSCT.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
11/06/2019
Locations: Northwestern University, Chicago, Illinois
Conditions: Crohn's Disease
Register for Updates
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
NCT03126864
Terminated
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn about the safety and tolerability of 3 different doses of CD33-CAR-T cells (referred to throughout the consent as "T-cells") in patients who have CD33-positive acute myeloid leukemia (AML) that is relapsed (has come back) or refractory (has not responded to treatment). CD33-CAR-T is made by genetically modifying (changing) your T-cells (... Read More
Gender:
ALL
Ages:
Between 1 year and 80 years
Trial Updated:
11/01/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia
Register for Updates
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
NCT00046852
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation and immunotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Randomized phase I/II trial to study the effectiveness of combining chemothe... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/31/2019
Locations: Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +1 locations
Conditions: Infection, Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003397
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell tran... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/31/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Lymphoma
Register for Updates
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia
NCT00003727
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with a peripheral stem cell transplant and immunotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: This phase II trial is studying giving chemotherapy together with a peripheral stem cell t... Read More
Gender:
ALL
Ages:
120 years and below
Trial Updated:
10/31/2019
Locations: Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland
Conditions: Leukemia
Register for Updates
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
NCT01492673
Completed
The purpose of this study is to find out what effects, good and/or bad treatment with a new combination of drugs, cyclophosphamide, topotecan, and bevacizumab has on the patient and their cancer. The medications, cyclophosphamide and topotecan, are standard drugs often used together for the treatment of cancer in children with either Ewing's sarcoma or neuroblastoma. Bevacizumab is an experimental drug called an antibody that targets a protein important in the growth of cancer cells called vas... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
10/28/2019
Locations: Phoenix Children'S Hospital, Phoenix, Arizona +6 locations
Conditions: Neuroblastoma, Sarcoma
Register for Updates
Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients
NCT00478452
Completed
This is a randomized Phase I/II study designed to assess the induction of an anti-tumor immune response; the effect of cyclophosphamide on the vaccine; and to assess safety in subjects with advanced ovarian cancer or primary serous peritoneal cancer given a multivalent DC vaccine, with or without a single dose of cyclophosphamide. Potential benefit may range from no direct benefit to the study participants to stimulation of the subject's own immune system to attack ovarian cancer to prevent rel... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/21/2019
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Register for Updates
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00003396
Completed
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation from related donors to prevent graft-versus-host disease in treating patients with hematologic cancer.
Gender:
ALL
Ages:
120 years and below
Trial Updated:
10/15/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Register for Updates
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00003398
Completed
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing graft-versus-host disease following bone marrow transplantation. PURPOSE: Phase IV trial to study the incidence of graft-versus-host disease in patients who have hematologic cancer and who are undergoing bone marrow transplantation from a donor.
Gender:
ALL
Ages:
50 years and below
Trial Updated:
10/15/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Anemia, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Register for Updates
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
NCT00003399
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy in treating patients who have multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/15/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
NCT00003401
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy in treating patients who have multiple myeloma that has been treated for longer than 12 months.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/15/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
NCT00005946
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic cancer that has relapsed following donor peripheral stem cell transplantation. PURPOSE: Phase I trial to study the effectiveness of chemotherapy plus donor white blood cell infusion in treating patients who have relapsed hematologic cancer following donor peripheral stem... Read More
Gender:
ALL
Ages:
120 years and below
Trial Updated:
10/15/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Register for Updates